Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GMED · against 159 other Healthcare companies of similar size
Ranked #27 of 160 · scores higher than 84% of peers
Bars: peers in each 10-point band of the valuation score18 peers with a valuation score of 70–79, including GMED · Click a bar to see the companies
Mainly thanks to its free cash flow yield, EBITDA yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | GMED | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 159 reported | 4.9% | 2.6% | 84% | 30% | |
| EBITDA yieldHigher is better · 159 reported | 9.9% | 4.7% | 89% | 50% | |
| Free cash flow yieldHigher is better · 94 reported | 7.0% | 2.2% | 92% | 20% | |
| Book yieldHigher is better · 158 reported | 44.6% | 18.6% | 83% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 5 | 11.6B USD | 94 | 58 | |
| 22 | 9.7B AUD (≈$6.4B) | 84 | 52 | |
| 24 | 1.85T JPY (≈$12.5B) | 79 | 55 | |
| 24 | 11.2B EUR (≈$12.3B) | 79 | 63 | |
| 26 | 69.1B BRL (≈$12.4B) | 78 | 57 | |
| 27 | 10.7B USD | 77 | 78 | |
| 28 | 99.2B CNY (≈$13.9B) | 74 | 67 | |
| 29 | 311.5B THB (≈$8.7B) | 73 | 62 | |
| 29 | 13.3B USD | 73 | 59 | |
| 29 | 18.5B USD | 73 | 54 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score